NCT00069446View on ClinicalTrials.gov

A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

October 31, 2004

Study Completion Date

October 31, 2004

Conditions
Foot Ulcer
Interventions
DRUG

rhuMAb VEGF (telbermin)

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY